Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.
Eye (Lond)
; 31(11): 1594-1599, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-28622321
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Agudeza Visual
/
Edema Macular
/
Retinopatía Diabética
/
Ranibizumab
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2017
Tipo del documento:
Article